Abbonarsi

Does fibrin sealant use in total knee replacement reduce transfusion rates? A non-randomised comparative study - 27/03/12

Doi : 10.1016/j.otsr.2011.10.012 
P. Massin , C. Scemama, C. Jeanrot, P. Boyer
Department of Orthopaedic Surgery, Bichat Claude-Bernard Teaching Hospital Center, Paris Diderot University, 46, rue Henri-Huchard, 75877 Paris cedex 18, France 

Corresponding author. Tel.: +33 1 40 24 75 03; fax: +33 1 40 25 71 84.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Summary

Background

Studies assessing fibrin sealants use during total knee replacement (TKR) have produced inconsistent results. We evaluated fibrin sealant therapy in TKR procedures performed without tourniquet and without postoperative drains.

Hypothesis

Use of a fibrin sealant during TKR decreases calculated total blood loss, thereby diminishing blood transfusion requirements and costs.

Patients and methods

We studied 62 patients with primary knee osteoarthritis who underwent TKR by the same surgeon between September 2009 and December 2010. Fibrin sealant was used only in the last 31 patients, who were compared to the first 31 patients regarding calculated total blood loss, blood transfusion rate, and mean number of red-blood-cell units used per patient. Costs were compared in the two groups.

Results

In the control group, mean total blood loss calculated using the method of Gross was 1.3±0.6L, 48% of patients required blood transfusions, and the mean number of units per patient was 0.9±1. In the fibrin-sealant group, 29% of patients required blood transfusions and the mean number of units was 0.6±0.9. The between-group differences in favour of the fibrin-sealant group were not statistically significant. In each group, compared with patients not requiring blood transfusions, patients needing transfusions had significantly lower starting preoperative haemoglobin values and a significantly greater positive difference between the calculated total blood loss and the maximum allowable blood loss. In the test group, the cost of the 31 units of fibrin sealant was 9743€ and the cost reduction due to using 11 fewer red-blood-cell units was only 3484€. Hospital stay was not significantly shorter in any of the two groups.

Discussion

Blood transfusion minimisation during TKR should rely chiefly on correcting preoperative anaemia and optimizing transfusion decisions based on the difference between the total blood loss and the maximum allowable blood loss. Fibrin sealant did not significantly diminish transfusion requirements in our study. Randomised studies in larger patient populations are needed. The cost of fibrin sealant may exceed the expected cost savings in relation with decreased blood transfusion requirements.

Level of evidence

Level III (before-after therapeutic study).

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Total knee replacement, Blood loss, Fibrin sealant


Mappa


© 2012  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 98 - N° 2

P. 180-185 - Aprile 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • Reliability of locked plating in tibial plateau fractures with a medial component
  • M. Ehlinger, M. Rahme, B.-K. Moor, A. Di Marco, D. Brinkert, P. Adam, F. Bonnomet
| Articolo seguente Articolo seguente
  • Oral thromboprophylaxis following total hip replacement: The issue of compliance
  • B. Lebel, M. Malherbe, S. Gouzy, J.-J. Parienti, J.-J. Dutheil, M.-T. Barrellier, C. Vielpeau

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.